BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 33198784)

  • 1. The molecular and gene/miRNA expression profiles of radioiodine resistant papillary thyroid cancer.
    Colombo C; Minna E; Gargiuli C; Muzza M; Dugo M; De Cecco L; Pogliaghi G; Tosi D; Bulfamante G; Greco A; Fugazzola L; Borrello MG
    J Exp Clin Cancer Res; 2020 Nov; 39(1):245. PubMed ID: 33198784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Genetic Duet of
    Liu J; Liu R; Shen X; Zhu G; Li B; Xing M
    J Nucl Med; 2020 Feb; 61(2):177-182. PubMed ID: 31375570
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical and molecular characterisation of metastatic papillary thyroid cancer according to radioiodine therapy outcomes.
    Simões-Pereira J; Saramago A; Rodrigues R; Pojo M; Pires C; Horta M; López-Presa D; Rito M; Cabrera R; Ferreira TC; Leite V; Cavaco BM
    Endocrine; 2024 May; 84(2):625-634. PubMed ID: 38102497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol.
    Iravani A; Solomon B; Pattison DA; Jackson P; Ravi Kumar A; Kong G; Hofman MS; Akhurst T; Hicks RJ
    Thyroid; 2019 Nov; 29(11):1634-1645. PubMed ID: 31637953
    [No Abstract]   [Full Text] [Related]  

  • 5. BRAF V600E and Retinoic Acid in Radioiodine-Refractory Papillary Thyroid Cancer.
    Groener JB; Gelen D; Mogler C; Herpel E; Toth C; Kender Z; Peichl M; Haufe S; Haberkorn U; Sulaj A; Zemva J; Kopf S; Nawroth PP; Brune M; Rudofsky G
    Horm Metab Res; 2019 Jan; 51(1):69-75. PubMed ID: 30396219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of RET rearrangements in papillary thyroid carcinoma using RT-PCR and FISH techniques - A molecular and clinical analysis.
    Musholt TJ; Staubitz JI; Antonio Cámara RJ; Musholt PB; Humberg D; Springer E; Schad A
    Eur J Surg Oncol; 2019 Jun; 45(6):1018-1024. PubMed ID: 30472213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The genetic duet of BRAF V600E and TERT promoter mutations predicts the poor curative effect of radioiodine therapy in papillary thyroid cancer.
    Cao J; Zhu X; Sun Y; Li X; Yun C; Zhang W
    Eur J Nucl Med Mol Imaging; 2022 Aug; 49(10):3470-3481. PubMed ID: 35501518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Noninferior response in BRAF(V600E) mutant nonmetastatic papillary thyroid carcinoma to radioiodine therapy.
    Li J; Liang J; Zhao T; Lin Y
    Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1034-9. PubMed ID: 26780618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcomes and molecular profile of differentiated thyroid cancers with radioiodine-avid distant metastases.
    Sabra MM; Dominguez JM; Grewal RK; Larson SM; Ghossein RA; Tuttle RM; Fagin JA
    J Clin Endocrinol Metab; 2013 May; 98(5):E829-36. PubMed ID: 23533233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Redifferentiation of BRAF V600E-Mutated Radioiodine Refractory Metastatic Papillary Thyroid Cancer After Treatment With Dabrafenib and Trametinib.
    Jafri S; Yaqub A
    Cureus; 2021 Aug; 13(8):e17488. PubMed ID: 34595070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of Subtypes of BRAF-Mutant Papillary Thyroid Cancer Defined by Their Thyroid Differentiation Score.
    Boucai L; Seshan V; Williams M; Knauf JA; Saqcena M; Ghossein RA; Fagin JA
    J Clin Endocrinol Metab; 2022 Mar; 107(4):1030-1039. PubMed ID: 34897468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NTRK and RET fusion-directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake.
    Lee YA; Lee H; Im SW; Song YS; Oh DY; Kang HJ; Won JK; Jung KC; Kwon D; Chung EJ; Hah JH; Paeng JC; Kim JH; Choi J; Kim OH; Oh JM; Ahn BC; Wirth LJ; Shin CH; Kim JI; Park YJ
    J Clin Invest; 2021 Sep; 131(18):. PubMed ID: 34237031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do Molecular Profiles of Primary
    Gomes-Lima CJ; Shobab L; Wu D; Ylli D; Bikas A; McCoy M; Feldman R; Lee W; Rao SN; Jensen K; Vasko V; Castro LC; Jonklaas J; Wartofsky L; Burman KD
    Front Endocrinol (Lausanne); 2021; 12():623182. PubMed ID: 33716974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-Iodine-Avid Disease Is Highly Prevalent in Distant Metastatic Differentiated Thyroid Cancer With Papillary Histology.
    Soe MH; Chiang JM; Flavell RR; Khanafshar E; Mendoza L; Kang H; Liu C
    J Clin Endocrinol Metab; 2022 Jul; 107(8):e3206-e3216. PubMed ID: 35556126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Robust Thyroid Gene Expression and Radioiodine Uptake Induced by Simultaneous Suppression of BRAF V600E and Histone Deacetylase in Thyroid Cancer Cells.
    Cheng W; Liu R; Zhu G; Wang H; Xing M
    J Clin Endocrinol Metab; 2016 Mar; 101(3):962-71. PubMed ID: 26751190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterizing Genetic Alterations Related to Radioiodine Avidity in Metastatic Thyroid Cancer.
    Mu Z; Zhang X; Sun D; Sun Y; Shi C; Ju G; Kai Z; Huang L; Chen L; Liang J; Lin Y
    J Clin Endocrinol Metab; 2024 Apr; 109(5):1231-1240. PubMed ID: 38060243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a Recurrent LMO7-BRAF Fusion in Papillary Thyroid Carcinoma.
    He H; Li W; Yan P; Bundschuh R; Killian JA; Labanowska J; Brock P; Shen R; Heerema NA; de la Chapelle A
    Thyroid; 2018 Jun; 28(6):748-754. PubMed ID: 29768105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LIMD2 Is Overexpressed in BRAF V600E-Positive Papillary Thyroid Carcinomas and Matched Lymph Node Metastases.
    Pinheiro Dos Santos MJC; Bastos AU; da Costa VR; Delcelo R; Lindsey SC; Colozza-Gama GA; Peng H; Rauscher FJ; Oler G; Cerutti JM
    Endocr Pathol; 2018 Sep; 29(3):222-230. PubMed ID: 29560564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Outcomes of Radioactive Iodine Redifferentiation Therapy in Previously Iodine Refractory Differentiated Thyroid Cancers.
    Toro-Tobon D; Morris JC; Hilger C; Peskey C; Durski JM; Ryder M
    Thyroid; 2024 Jan; 34(1):70-81. PubMed ID: 37917101
    [No Abstract]   [Full Text] [Related]  

  • 20. AXL Is a Novel Predictive Factor and Therapeutic Target for Radioactive Iodine Refractory Thyroid Cancer.
    Collina F; La Sala L; Liotti F; Prevete N; La Mantia E; Chiofalo MG; Aquino G; Arenare L; Cantile M; Liguori G; Di Gennaro F; Pezzullo L; Losito NS; Vecchio G; Botti G; Melillo RM; Franco R
    Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31181609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.